AYOXXA and Grünenthal validate protein multiplexing technology in inflammation study

AYOXXA Biosystems and pain therapeutics specialist Grünenthal have undertaken a study using AYOXXA's protein multiplexing technology platform to analyse an inflammation marker at very low concentrations released from human cells following treatment in cell culture experiments. The collaboration aims to develop improved methods for clinical biomarker detection in order to accelerate the development of new pain and inflammation drugs.

Grünenthal provided proprietary samples while AYOXXA contributed in-depth experience in immunoassay development to simultaneously detect multiple targets down to single digit picogramm/ml concentrations. Applications include biological samples with very low initial volume, previously inaccessible by other immunoassays. Protein multiplex analysis for highly valuable samples will open new strategies to improve clinical diagnostic and treatment development optimised for individual patients’ needs.        

Michael Rasche, corporate vice president global commercial operations of AYOXXA Biosystems, said: “To collaborate with an important pharma partner such as Grünenthal supports our strategy to become the protein multiplex testing platform for researchers in academia as well as in the industry. We are currently starting key projects in Europe as well as in the US and are ramping up our capacities to increase our project pipeline short-term."

Dr. Torsten Dunkern, director and head of cellular biology, Grünenthal, said: “The successful cross-validation of AYOXXA´s technology in comparison to homogenous detection methods for analytes used in Grünenthal´s drug discovery will facilitate the progression and broader use of its technology into pharmacodynamics studies.”

Dr. Henning Steinhagen, senior vice president and head of drug discovery, Grünenthal, added: “AYOXXA’s proprietary technology performed successfully in our hands and we can see a lot of potential future applications.”